Capital World Investors In8 Bio, Inc. Transaction History

Capital World Investors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.02 - $4.68 $51,021 - $118,207	-25,258 Reduced 3.16%	774,742 $1.88 Million
Q1 2022 May 19, 2022	BUY	$2.76 - $4.6 $2.21 Million - $3.68 Million	800,000 New	800,000 $2.78 Million
Q1 2022 May 16, 2022	SELL	$2.76 - $4.6 $2.21 Million - $3.68 Million	-800,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.71 - $10.0 $5.37 Million - $8 Million	800,000 New	800,000 $5.52 Million

7.62M

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $6.13M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.